Announcement on Obtaining Drug Registration Certificate for Rivastigmine Transdermal Patch
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Obtaining Drug Registration Certificate for Rivastigmine Transdermal Patch
Filed with SSE · · 2 pages · Chinese
Release
Humanwell Healthcare (Group) Co.,Ltd. on 6ix
Earlier from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Adding Extraordinary Proposal to the 3rd Extraordinary General Meeting in 2025
- Humanwell Healthcare (Group): >Humanwell PuraCap Pharmaceutical LLC Announces Successful FDA Inspection
Later from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
- Announcement on Approval of Drug Registration Certificate for Drospirenone and Ethinylestradiol Tablets
- Announcement on HW241045 Tablets Obtaining Notice of Approval for Drug Clinical Trials
- Announcement on Implementation of Dividend Distribution for 2024
- Announcement on Obtaining Drug Registration Certificate for Remimazolam Besylate for Injection with Increased Indications
Follow Humanwell Healthcare (Group) Co.,Ltd into a list and get an email when it puts out news.
Follow Humanwell Healthcare (Group) Co.,Ltd